[Expression and Clinical Significance of Serum HDAC2 in Patients with Acute Myeloid Leukemia].

Abstract

Objective: To investigate the expression of serum histone deacetylase 2 (HDAC2) in patients with acute myeloid leukemia (AML) and its clinical significance.

Methods: The 150 AML patients who received treatment in our hospital from April 2017 to April 2019 were included as AML group, and further divided into survival group (108 cases) and death group (42 cases) according to their survival status. In addition, 100 health individuals undergoing health examination in the same period were included as control group. The expression of HDAC2 in serum was detected by real-time quantitative PCR. Cox regression was used to analyze the influencing factors of adverse prognosis. The predictive effect of serum HDAC2 for the adverse prognosis of AML patients was evaluated by the receiver operating characteristic (ROC) curve.

Results: Compared with the control group, the expression of serum HDAC2, interleukin (IL)-6, tumor necrosis factor (TNF)-α, IL-1β and C-reactive protein (CRP) in AML group was obviously increased (all P <0.05). Compared with the survival group, the expression of serum HDAC2 in the death group was also increased (P <0.05). Serum HDAC2 was positively correlated with IL-6, TNF-α, IL-1β and CRP in AML patients (r =0.567, 0.559, 0.623, 0.537). According to Cox regression analysis, the IL-6, TNF-α, IL-1β and HDAC2 were independent risk factors affecting the prognosis of AML patients (all P <0.05). ROC analysis showed that the AUC of serum HDAC2 level in predicting the adverse prognosis of AML was 0.862.

Conclusion: The expression level of serum HDAC2 in AML patients is increased, which has positive correlations with IL-6, TNF-α, IL-1β and CRP. HDAC2 is an independent risk factor for the poor prognosis of AML patients, and has a high predictive value.